Impact Therapeutics FY26 H1 net loss narrows 29.5% to RMB 90.81 million; revenue rises to RMB 105.19 million

PUBT · 2d ago
Impact Therapeutics FY26 H1 net loss narrows 29.5% to RMB 90.81 million; revenue rises to RMB 105.19 million
  • Impact Therapeutics reported revenue of RMB 105.19 million, up more than quadrupled from a year earlier.
  • Loss for the period narrowed 29.5% to RMB 90.81 million; basic and diluted loss per share improved to RMB 0.37.
  • R&D expenses rose 13.1% to RMB 97.64 million; selling and distribution expenses climbed to RMB 22.85 million.
  • Cash and financial assets jumped more than quadrupled to RMB 1.07 billion; net assets swung to RMB 775.77 million.
  • Senaparib China revenue reached RMB 70.4 million; July deal with Pharmanovia carries up to EUR 423.5 million milestones.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Impact Therapeutics Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260831-12307927), on August 31, 2026, and is solely responsible for the information contained therein.